We've now confirmed that Emgality is on the PBAC agenda for July. This means that Emgality could be made available and recommended for the PBS before Aimovig has an opportunity to re-attempt getting a recommendation from PBAC. The next meeting where Aimovig could be considered again is the November meeting. 

Public submissions to PBAC on the Emgality (GALCANEZUMAB) listing can be made up until June 12. Use this form to submit your comments and make sure we are heard on why these medications are so important. http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form

Headache Australia has not yet updated its website from the Aimovig listing, but has tips about what to include on the submission here: https://headacheaustralia.org.au/cgrp-update-february-2019/

Please share this information (and the petition!) everywhere you can. Thanks.